Sort

Search

02/12/2022 Biologic treatment of psoriasis in oncologic patients
Rusinol, L, Camina-Conforto, G, Puig, L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12)DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4.600(Q2/3D).
01/12/2022 Water T2 could predict functional decline in patients with dysferlinopathy
Moore, U, Araujo, ECD, Reyngoudt, H, Gordish-Dressman, H, Smith, FE, Wilson, I, James, M, Mayhew, A, Rufibach, L, Day, JW, Jones, KJ, Bharucha-Goebel, DX, Salort-Campana, E, Pestronk, A, Walter, MC, Paradas, C, Stojkovic, T, Mori-Yoshimura, M, Bravver, E, Pegoraro, E, Mendell, JR, Bushby, K, Blamire, AM, Straub, V, Carlier, PG, Diaz-Manera, J. Water T2 could predict functional decline in patients with dysferlinopathy. Journal of Cachexia Sarcopenia and Muscle. 2022; 13(6)DOI:10.1002/jcsm.13063. PMID:36058852. IF:8.900(Q1/1D).
01/12/2022 Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington's Disease
Sampedro, F, Martinez-Horta, S, Perez-Perez, J, Perez-Gonzalez, R, Horta-Barba, A, Campolongo, A, Izquierdo, C, Aracil-Bolanos, I, Rivas, E, Puig-Davi, A, Pagonabarraga, J, Gomez-Anson, B, Kulisevsky, J. Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington's Disease. Clinical Neuroradiology. 2022; 32(4)DOI:10.1007/s00062-022-01150-5. PMID:35238950. IF:2.800(Q2/5D).
01/12/2022 Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers
Marin-Lahoz, J, Martinez-Horta, S, Pagonabarraga, J, Horta-Barba, A, Aracil-Bolanos, I, Bejr-kasem, H, Sampedro, F, Campolongo, A, Kulisevsky, J. Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers. ANNALS OF NEUROLOGY. 2022; 92(6)DOI:10.1002/ana.26486. PMID:36054656. IF:11.200(Q1/1D).
01/12/2022 Endothelial NO synthase 786T/T polymorphism increases hemorrhagic transformation after endovascular thrombectomy
De la Riva, P, Rodriguez-Antiguedad, J, Gomez, V, Arenaza, G, Gorostidi, A, Diez, N, De Arce, A, Martinez-Zabaleta, M, Gonzalez, F, Luttich, A, Garmendia, E, Sola, A, Larrea, JA, Bergareche, A, Sobrino, T. Endothelial NO synthase 786T/T polymorphism increases hemorrhagic transformation after endovascular thrombectomy. NITRIC OXIDE-BIOLOGY AND CHEMISTRY. 2022; 129DOI:10.1016/j.niox.2022.08.006. PMID:36067953. IF:3.900(Q2/5D).
01/12/2022 Delineating apathy profiles in Huntington's disease with the short-Lille Apathy Rating Scale
De Paepe, AE, Garcia-Gorro, C, Martinez-Horta, S, Perez, JP, Kulisevsky, J, Rodriguez-Dechicha, N, Vaquer, I, Subira, S, Calopa, M, Santacruz, P, Munoz, E, Mareca, C, Ruiz-Idiago, J, De Diego-Balaguer, R, Camara, E. Delineating apathy profiles in Huntington's disease with the short-Lille Apathy Rating Scale. PARKINSONISM & RELATED DISORDERS. 2022; 105DOI:10.1016/j.parkreldis.2022.10.025. PMID:36395542. IF:4.100(Q2/3D).
01/12/2022 Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
Pagonabarraga, J, Perez-Gonzalez, R, Bejr-kasem, H, Marin-Lahoz, J, Horta-Barba, A, Martinez-Horta, S, Aracil-Bolanos, I, Sampedro, F, Campolongo, A, Rivas, E, Puig-Davi, A, Ruiz-Barrios, I, Perez-Perez, J, Pascual-Sedano, B, Kulisevsky, J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. PARKINSONISM & RELATED DISORDERS. 2022; 105DOI:10.1016/j.parkreldis.2022.05.020. PMID:35752549. IF:4.100(Q2/3D).
01/12/2022 Trial of Deferiprone in Parkinson's Disease
Devos, D, Labreuche, J, Rascol, O, Corvol, JC, Duhamel, A, Delannoy, PG, Poewe, W, Compta, Y, Pavese, N, Ruzicka, E, Dusek, P, Post, B, Bloem, BR, Berg, D, Maetzler, W, Otto, M, Habert, MO, Lehericy, S, Ferreira, J, Dodel, R, Tranchant, C, Eusebio, A, Thobois, S, Marques, AR, Meissner, WG, Ory-Magne, F, Walter, U, de Bie, RMA, Gago, M, Vilas, D, Kulisevsky, J, Januario, C, Coelho, MVS, Behnke, S, Worth, P, Seppi, K, Ouk, T, Potey, C, Leclercq, C, Viard, R, Kuchcinski, G, Lopes, R, Pruvo, JP, Pigny, P, Garcon, G, Simonin, O, Carpentier, J, Rolland, AS, Nyholm, D, Scherfler, C, Mangin, JF, Chupin, M, Bordet, R, Dexter, DT, Fradette, C, Spino, M, Tricta, F, Ayton, S, Bush, AI, Devedjian, JC, Duce, JA, Cabantchik, I, Defebvre, L, Deplanque, D, Moreau, C. Trial of Deferiprone in Parkinson's Disease. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(22)DOI:10.1056/NEJMoa2209254. PMID:36449420. IF:158.500(Q1/1D).